Blog
    Regulatory UpdateFor PhysiciansMarch 26, 2026

    FDA peptide compounding status and FAERS safety signals

    Review the regulatory status of BPC-157, semaglutide, and thymic peptides, including 503A compounding categories and emerging FAERS safety signals.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Clinical Question

    What are the current regulatory statuses, compounding restrictions, and emerging safety signals for peptide therapies including GLP-1 agonists, BPC-157, and thymic peptides as of early 2026?

    Evidence Snapshot

    • Regulatory Analysis: 10+ peptides reviewed for FDA approval and compounding status.
    • Safety Data: FAERS signal analysis for semaglutide (187,757 GLP-1 RA reports through 2023) and regulatory warning letters.
    • Compounding Status: Review of Section 503A and 503B categories as of September 2023 and September 2024.
    • Clinical Outcomes: Phase II/III data for semaglutide, tirzepatide, retatrutide, and thymosin alpha-1.

    What the Research Shows

    Regulatory and Compounding Status As of March 2026, several widely discussed peptides remain non-FDA approved and subject to significant compounding restrictions. Specifically, BPC-157, TB-500, and GHK-Cu are classified as Category 2 bulk substances under Section 503A. The FDA cite "significant safety risk" and "immunogenicity concerns" for BPC-157, rendering it ineligible for routine compounding. TB-500 is cited for immunogenicity risk and a lack of human exposure data.

    Several peptides previously nominated for compounding have seen their nominations withdrawn or their status changed. Tesamorelin, though FDA-approved for HIV lipodystrophy (showing an 18% VAT reduction in Phase III trials, PMID: 18046028), is not currently listed as being in shortage. In contrast, substances like Ipamorelin and CJC-1295 had their nominations withdrawn and were removed from compounding eligibility in September 2024. The FDA specifically noted safety issues such as increased heart rate for CJC-1295.

    Thymosin Alpha-1, while approved in over 35 countries as Zadaxin, is not FDA-approved. It was moved to Category 2 in September 2023 and removed pending advisory review in September 2024, yet it remains a substance of concern under interim policy. Clinical data for Thymosin Alpha-1 has been mixed; a Phase III trial for sepsis (NCT02867267) reported no mortality reduction (PMID: 39814420).

    Safety Signal Analysis Postmarketing surveillance via FAERS for semaglutide identifies several established and emerging signals. Gastrointestinal events such as nausea and vomiting are categorized as "Strong (ROR elevated)" and are dose-dependent. More severe gastrointestinal signals include acute pancreatitis (moderate signal, PRR elevated) and emerging signals for intestinal obstruction or ileus, which were added to the label postmarketing.

    Two emerging signals currently under close observation include:

    • NAION (Nonarteritic Anterior Ischemic Optic Neuropathy): 96 cases reported through December 2024, with a formal EMA review initiated in January 2025. The median onset is 186 days.
    • Pulmonary Aspiration: An emerging signal added to the Ozempic label in 2025, linked to delayed gastric emptying risks during general anesthesia.

    Warning Letters Regulatory enforcement has been documented through warning letters. Specifically, Tailor Made Compounding received a warning letter in 2020 involving BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, and GHRP-2. Predator Nutrition also received a warning letter in October 2020 regarding BPC-157.

    Mechanism

    In Phase III and Phase II trials, different peptides have demonstrated the following results:

    • Semaglutide: Achieved a 14.9% weight loss in the STEP 1 trial and a 20% MACE reduction in the SELECT cardiovascular outcomes trial.
    • Tirzepatide: Demonstrated a 22.5% weight loss in the SURMOUNT-1 trial and showed superiority over semaglutide in the SURMOUNT-5 trial.
    • Retatrutide: A Phase II dose-finding study showed 24.2% weight loss at a 12mg dose.
    • Tesamorelin: Acts as a growth hormone-releasing factor analog, resulting in an 18% reduction in visceral adipose tissue (VAT).

    Limitations of the Evidence

    A primary limitation for peptides like BPC-157 and TB-500 is the absolute lack of human safety and exposure data cited by the FDA. While peptides such as Selank and Semax are approved in Russia (for general use and stroke, respectively), there is a lack of FDA-recognized clinical trials for these indications in the United States.

    Furthermore, while psychiatric signals like suicidal ideation are under evaluation and included in the semaglutide label, current FDA data do not support a higher risk versus the background population. Many signals, such as NAION and pulmonary aspiration, remain in the "emerging" category and require further formal review to establish definitive causality.

    Clinical Takeaway

    Clinicians should distinguish between FDA-approved peptides with established safety profiles (e.g., semaglutide, tirzepatide, tesamorelin) and those classified as Category 2 substances (e.g., BPC-157, TB-500), which are ineligible for routine compounding due to safety and immunogenicity concerns. Monitoring for emerging gastrointestinal and ocular safety signals is warranted as postmarketing data continues to accumulate through 2025 and 2026.

    Sources

    1. FDA Regulatory Status Records (March 2026)
    2. FAERS Safety Signal Database (2023-2025 data)
    3. Clinical Trial Records: NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT00451282, NCT02867267

    Referenced Peptides

    bpc 157semaglutidetirzepatidetesamorelinthymosin alpha 1

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.